症状引导缩短BCG灌注时间:North-REG随机试验结果
在225例非肌层浸润性膀胱癌患者中,症状引导的BCG灌注时间缩短(至60或30分钟)较标准120分钟显著降低诱导期第3周和第6周的尿急发生率,以及维持期第9周全身症状和乏力发生率,但治疗完成率两组相似(38%对40%)。
要点
- 症状引导缩短BCG灌注时间可降低诱导期尿急发生率。
- 维持期全身症状和乏力在干预组显著减少。
- 治疗完成率未因灌注时间缩短而改变。
核心结论
- 症状引导的BCG灌注时间缩短可能减轻局部尿急和全身毒性,改善治疗耐受性,但不影响治疗完成率。
研究设计与样本
- 多国随机对照试验(North-REG Dwell Time Study,NCT04701151),225例患者提供每日电子患者报告结局数据,1:1随机分层因素包括临床中心、性别和合并原位癌。
主要发现
- 基线时对照组69%、干预组71%报告已有症状,主要为尿频和尿急等下尿路症状。
- 诱导期第3周尿急发生率干预组34%对对照组47%(P=0.04),第6周32%对49%(P=0.01)。
- 维持期第9周全身症状发生率干预组30%对对照组61%(P<0.001),乏力22%对47%(P=0.001)。
- 15次灌注方案总依从率干预组38%、对照组40%。
临床怎么用
- 对BCG灌注中出现尿急或全身症状的患者,可考虑基于实时症状严重程度将灌注时间从120分钟缩短至60或30分钟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the impact of personalized dwell-time (DT) reductions on symptom prevalence and systemic toxicities in patients undergoing Bacillus Calmette-Guérin (BCG) instillation for non-muscle invasive bladder cancer (NMIBC). METHODS: Within a multinational randomized controlled trial (North-REG Dwell Time Study [NCT04701151]), 225 patients provided daily electronic patient-reported outcomes data during BCG induction and maintenance cycles. Participants were randomized 1:1, stratified by clinical site, sex, and concomitant carcinoma in situ, to either a standard care arm (control) or an intervention arm. Toxicity was analysed using a 'worst-day' principle to capture peak symptom burden. All patients initially received a standard 120-min DT. In the intervention group, algorithm-guided DT reductions (to 60 or 30 min) were triggered by real-time symptom severity, whereas the control group maintained a 120-min DT. RESULTS: At baseline, 69% vs. 71% (control vs. intervention) of participants reported pre-existing symptoms, primarily lower urinary tract symptoms such as pollakiuria and urgency. During induction, the intervention group experienced significantly lower rates of urgency at week 3 (34% vs. 47%, P = 0.04) and week 6 (32% vs. 49%, P = 0.01). Significant reductions were also observed during maintenance at week 9 for systemic symptoms (30% vs. 61%, P < 0.001) and fatigue (22% vs. 47%, P = 0.001). Total adherence to the 15-instillation protocol was 38% in the intervention group and 40% in the control group. CONCLUSION: Daily electronic patient-reported outcomes monitoring revealed that patients with NMIBC have a high baseline symptom burden prior to BCG therapy. Symptom-guided DT reductions may reduce local urgency and systemic toxicity and improve treatment tolerability. However, treatment completion does not seem to be affected.
引用
- Munk L, Hyldgaard JM, Kumasegaram V, et al. Symptom-guided reduction of BCG dwell time: findings from the north-REG randomized trial. BJU Int. 2026. PMID: 42538302. doi:10.1111/bju.70396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。